Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2017

01-12-2017 | Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences

Authors: Jose Ignacio Vargas, Juan Pablo Arab, Fernando Bessone, Maria Isabel Lucena, Raul J. Andrade, Marco Arrese

Published in: Current Hepatology Reports | Issue 4/2017

Login to get access

Abstract

Purpose of Review

The purpose of this review was to analyze the current evidence regarding the incidence, mechanisms, and outcomes of drug-induced liver injury (DILI) and hepatotoxicity in patients with metabolic syndrome and nonalcoholic fatty liver disease.

Recent Findings

DILI is a complex clinical entity. Although uncommon, its incidence and diagnosis have been rising in recent years as basic research and clinical databases provide information about its etiology, clinical course, and prognosis. The prevalence of metabolic syndrome and non-alcoholic fatty liver disease is on the rise in western countries. Recently, features of the metabolic syndrome have been identified as factors affecting the phenotype and evolution of DILI, both in pre-clinical and clinical research.

Summary

In the present review, we summarize current evidence regarding the influence of features of metabolic syndrome in the presentation, clinical course, and prognosis of DILI.
Literature
1.
Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–66. quiz 67 CrossRefPubMed
2.
• Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–14. Excellent general review on drug-associated and host factors for DILI. CrossRefPubMed
3.
4.
Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis. 2014;18(1):165–78.CrossRefPubMed
5.
• Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212–32. An updated and in-depth review on the role of NAFLD as a risk factor for DILI. PubMedPubMedCentral
6.
Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571–9.CrossRefPubMed
7.
8.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRefPubMed
9.
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2017.
10.
Targher G, Byrne CDA. Perspective on metabolic syndrome and nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2015;13(6):235–8.CrossRefPubMed
11.
Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Nat Acad Sci U.S.A. 1997;94(6):2557–62.CrossRef
12.
Chu MJ, Hickey AJ, Phillips AR, Bartlett AS. The impact of hepatic steatosis on hepatic ischemia-reperfusion injury in experimental studies: a systematic review. Biomed Res Int. 2013;2013:192029.PubMedPubMedCentral
13.
Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of non-alcoholic fatty liver disease. Annual Review Pathology Mechanisms Disease. 2018 (in press).
14.
Liu W, Baker SS, Baker RD, Zhu L. Antioxidant mechanisms in nonalcoholic fatty liver disease. Curr Drug Targets. 2015;16(12):1301–14.CrossRefPubMed
15.
Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1497–507.CrossRefPubMed
16.
Nair S, PC V, Arnold C, Diehl AM, Hepatic ATP. Reserve and efficiency of replenishing: comparison between obese and nonobese normal individuals. Am J Gastroenterol. 2003;98(2):466–70.PubMed
17.
Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282(17):1659–64.CrossRefPubMed
18.
Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci. 2017;106(9):2282–94.CrossRefPubMed
19.
20.
Aubert J, Begriche K, Delannoy M, Morel I, Pajaud J, Ribault C, et al. Differences in early acetaminophen hepatotoxicity between obese ob/ob and db/db mice. J Pharmacol Exp Ther. 2012;342(3):676–87.CrossRefPubMed
21.
• Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opinion on Drug Metabolism & Toxicology. 2017;13(6):625–40. An updated review on NAFLD-associated liver functions changes and its impact in the clinical setting. CrossRef
22.
Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–25. 25 e1-3; quiz e19-20CrossRefPubMed
23.
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMed
24.
Bessone F, Hernandez N, Lucena MI, Andrade RJ. Latin Dili Network L, Spanish Dili R. The Latin American DILI Registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci. 2016;17(3):313.CrossRefPubMedPubMedCentral
25.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology. 2015;148(7):1340–52 e7.CrossRefPubMedPubMedCentral
26.
Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRefPubMed
27.
Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65(3):532–42.CrossRefPubMed
28.
Ruiz-salas A, Gonzalez Jimenez A, Stephens C, Medina-Caliz I, Hidalgo R, Robles-diaz M, et al. Influence of body mass index and metabolic risk factors on the phenotype and clinical expression of drug-induced liver injury (abstract). Ann Hepatol. 2014;13(5):601.
29.
Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55(3):683–91.CrossRefPubMed
30.
Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106.CrossRefPubMed
31.
Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci. 2016 17(5).
32.
•• Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154–64. An updated and in-depth review on current concepts on DILI. CrossRefPubMedPubMedCentral
33.
Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61(1):153–60.CrossRefPubMed
34.
Lee TH, Kim WR, Poterucha JJ. Evaluation of elevated liver enzymes. Clin Liver Dis. 2012;16(2):183–98.CrossRefPubMed
35.
Dakhoul L. N. C. Causality assessment for suspected drug-induced liver injury in patients with underlying chronic liver disease. Clinical Liver Disease. 2017;9(3):63–5.CrossRef
36.
37.
Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nature reviews. Gastroenterology & hepatology. 2011;8(4):202–11.
38.
Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100(19):2025–34.CrossRefPubMed
39.
Kum LC, Chan WW, Hui HH, Wong GW, Ho SS, Sanderson JE, et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. Clin Cardiol. 2006;29(7):295–9.CrossRefPubMed
40.
Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther. 2004;75(4):342–51.CrossRefPubMed
41.
Mattar W, Juliar B, Gradus-Pizlo I, Kwo PY. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointest Liver Dis JGLD. 2009;18(4):419–23.
42.
Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–80.CrossRefPubMed
43.
Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60(2):679–86.CrossRefPubMedPubMedCentral
44.
• Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial. J Clin Endocrinol Metab. 2017;102(8):2950–61. A prospective study on safety of statins in biopsy-proven NASH. CrossRefPubMed
45.
Del Ben M, Baratta F, Polimeni L, Pastori D, Loffredo L, Averna M, et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis NMCD. 2017;27(2):161–7.CrossRefPubMed
46.
Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol 2017
47.
Vargas JI, Arrese M, Shah VH, Arab JP. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Current Gastroenterol Rep. 2017;19(9):43.CrossRef
48.
Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63(3):705–12.CrossRefPubMed
49.
Stika CS. Methotrexate: the pharmacology behind medical treatment for ectopic pregnancy. Clin Obstet Gynecol. 2012;55(2):433–9.CrossRefPubMed
50.
Candia R, Ruiz A, Torres-Robles R, Chavez-Tapia N, Mendez-Sanchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol JEADV. 2015;29(4):656–62.CrossRefPubMed
51.
Bath RK, Brar NK, Forouhar FA, Wu GYA. Review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15(10):517–24.CrossRefPubMed
52.
Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46(6):1111–8.CrossRefPubMed
53.
Berends MA, Snoek J, de Jong EM, van de Kerkhof PC, van Oijen MG, van Krieken JH, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther. 2006;24(5):805–11.CrossRefPubMed
54.
Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18(1):47–66.CrossRefPubMed
55.
56.
Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;180(1):129–34.CrossRefPubMed
57.
Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330(7497):932.CrossRefPubMedPubMedCentral
58.
Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet. 1999;353(9146):36–7.CrossRefPubMed
59.
Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology. 2010;52(4):1258–65.CrossRefPubMed
60.
61.
Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther. 2007;321(2):526–35.CrossRefPubMed
62.
Birzniece V, Barrett PHR, Ho KKY. Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development. Eur J Endocrinol. 2017;177(2):137–43.CrossRefPubMed
63.
Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therapeut Adv Gastroenterol. 2012;5(3):199–207.CrossRef
64.
Yan M, Wang J, Xuan Q, Dong T, He J, Zhang Q. The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer. Clinical Breast Cancer. 2017;17(3):195–203.CrossRefPubMed
65.
Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet. Gastroenterol Hepatol. 2017;2(3):211–23.
66.
67.
McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. Crit Rev Oncol Hematol. 2013;88(2):404–15.CrossRefPubMed
68.
Makowiec F, Mohrle S, Neeff H, Drognitz O, Illerhaus G, Opitz OG, et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2011;15(1):153–64.CrossRef
69.
Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145(4):362–71.CrossRefPubMed
70.
Taing KD, O'Brien TJ, Williams DA, French CR. Anti-epileptic drug combination efficacy in an in vitro seizure model—phenytoin and valproate, lamotrigine and valproate. PloS one. 2017;12(1):e0169974.CrossRefPubMedPubMedCentral
71.
Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55(5):729–32.CrossRefPubMed
72.
Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 2009;86(1):42–7.CrossRefPubMed
73.
Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 2014;34(7):e171–9.CrossRefPubMed
74.
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.CrossRefPubMed
Metadata
Title
Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences
Authors
Jose Ignacio Vargas
Juan Pablo Arab
Fernando Bessone
Maria Isabel Lucena
Raul J. Andrade
Marco Arrese
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 4/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0380-8

Other articles of this Issue 4/2017

Current Hepatology Reports 4/2017 Go to the issue

Fatty Liver Disease (S Harrison and J George, Section Editors)

Non-alcoholic Fatty Liver Disease in Non-obese Patients

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Hepatotoxicity of New Antitumor Agents

Fatty Liver Disease (S Harrison and J George, Section Editors)

Role of Exercise in NAFLD/NASH: What is the Right Prescription?

Drug-Induced Liver Injury (F Bessone and R Andrade, Section Editors)

Autoimmune Hepatitis-Induced by Drugs: a Challenging Diagnosis

Fatty Liver Disease (S Harrison and J George, Section Editors)

Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C

Portal Hypertension (E Tsochatzis and J Abraldes, Section Editors)

Endoscopic Therapy for Variceal Bleeding: from Patient Preparation to Available Techniques and Rescue Therapies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits